It may be comforting to know that other people have been in your position. Hear real patients and caregivers share their experience with Gamifant.
Watch Mack share his experience as a teen diagnosed with primary HLH treated with Gamifant.
View Important Safety Information, including Patient Medication Guide, for Gamifant.
What is GAMIFANT?
Important Safety Information
What is GAMIFANT?
Gamifant (emapalumab-lzsg) is a prescription medicine used for the treatment of hemophagocytic lymphohistiocytosis (HLH) in adults and children (newborn and older) with:
Important Safety Information
Gamifant can cause serious side effects including:
Before starting Gamifant, tell your doctor if you:
After starting Gamifant, tell your healthcare provider if:
Your healthcare provider may give you medicine to help prevent certain infections before you receive Gamifant and will monitor you closely for signs and symptoms of infections during treatment with Gamifant.
Infusion Reactions. These are common, can also be severe, and can happen during or shortly after treatment with Gamifant. Your healthcare provider may temporarily stop your infusion and treat your symptoms before continuing your infusion if you have severe infusion reactions. Tell your healthcare provider right away if you get any of the following symptoms:
Before starting Gamifant, tell your doctor about all of your medical conditions including if you:
Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.
The most common side effects of Gamifant in people with primary HLH include: infections, high blood pressure (hypertension), and fever.
The most common side effects of Gamifant in people with HLH/MAS in Still’s disease include: viral infection and rash.
These are not all the possible side effects of Gamifant. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
Please see Patient Medication Guide for Gamifant.
What is GAMIFANT?
Important Safety Information
What is GAMIFANT?
Gamifant (emapalumab-lzsg) is a prescription medicine used for the treatment of hemophagocytic lymphohistiocytosis (HLH) in adults and children (newborn and older) with:
Important Safety Information
Gamifant can cause serious side effects including:
Before starting Gamifant, tell your doctor if you:
After starting Gamifant, tell your healthcare provider if:
Your healthcare provider may give you medicine to help prevent certain infections before you receive Gamifant and will monitor you closely for signs and symptoms of infections during treatment with Gamifant.
Infusion Reactions. These are common, can also be severe, and can happen during or shortly after treatment with Gamifant. Your healthcare provider may temporarily stop your infusion and treat your symptoms before continuing your infusion if you have severe infusion reactions. Tell your healthcare provider right away if you get any of the following symptoms:
Before starting Gamifant, tell your doctor about all of your medical conditions including if you:
Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.
The most common side effects of Gamifant in people with primary HLH include: infections, high blood pressure (hypertension), and fever.
The most common side effects of Gamifant in people with HLH/MAS in Still’s disease include: viral infection and rash.
These are not all the possible side effects of Gamifant. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
Please see Patient Medication Guide for Gamifant.
NOW APPROVED
Gamifant is now approved for HLH/MAS in Still’s disease.
We are excited to announce that Gamifant® (emapalumab-lzsg) has received FDA approval for the treatment of adults and children (newborn and older) with HLH/macrophage activation syndrome (MAS) in known or suspected Still’s disease, including systemic Juvenile Idiopathic Arthritis (sJIA), when glucocorticoids have not worked well enough or cannot be tolerated, or with MAS that has come back.
Please see Important Safety Information and Med Guide for more information.
PP-27769 06/25